MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment
- PMID: 38953463
- DOI: 10.1111/all.16212
MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment
References
REFERENCES
-
- Saini S. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin N Am. 2014;34(1):33‐52. http://search.proquest.com/docview/1560105945/
-
- Bartko EA, Elberling J, Blom LH, Poulsen LK, Jensen BM. Elevated, FcεRI‐dependent MRGPRX2 expression on basophils in chronic urticaria. Skin Health Dis. 2022;3:e195. doi:10.1002/ski2.195
-
- Xie G, Yang H, Peng X, et al. Mast cell exosomes can suppress allergic reactions by binding to IgE. J Allergy Clin Immunol. 2018;141(2):788‐791. doi:10.1016/j.jaci.2017.07.040
-
- Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M. Plasma levels of matrix metalloproteinase‐9 in chronic urticaria patients correlate with disease severity and C‐reactive protein but not with circulating histamine‐releasing factors. Clin Exp Allergy. 2010;40(6):875‐881. doi:10.1111/j.1365-2222.2010.03473.x
-
- Bartko EA, Blom LH, Elberling J, Poulsen LK, Jensen BM. Expression of CCR8 and CCX‐CKR on basophils in chronic urticaria is amplified by IgE‐mediated activation. Biomedicine. 2023;11(6):1537. doi:10.3390/biomedicines11061537
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
